scholarly journals Description of selected diagnostic tools in assessing the risk of venous thromboembolic disease

2016 ◽  
Vol 15 (1) ◽  
pp. 5-8
Author(s):  
Renata Piotrkowska ◽  
Piotr Jarzynkowski ◽  
Janina Książek
Keyword(s):  
Pulmonary Embolism ◽  
World Literature ◽  
Common Factor ◽  
Medical Problem ◽  
Thromboembolic Disease ◽  
Diagnostic Tools ◽  
Venous Thromboembolic Disease ◽  
Vein Thrombosis ◽  
Venous Thromboembolic ◽  
Deep Vein

AbstractIntroduction. Deep vein thrombosis (DVT) and its most severe complication, pulmonary embolism (PE) is an interdisciplinary medical problem. Despite a wealth of knowledge, pulmonary embolism is the cause of about 10% of deaths among hospitalized patients and the most common factor which can be prevented. Therefore correct, rapid diagnosis of the patient’s assessment of the risk of sudden death and the quick implementation of treatment are essential to reduce mortality in this disease and prevent its distant complications.Aim of the study. The aim of this paper is to discuss on the basis of Polish and world literature the selected diagnostic tools in assessing the risk of venous thromboembolic disease.

The accuracy of the diagnosis of deep vein thrombosis in patients with prior venous thromboembolic disease or severe varicose veins

1981 ◽  
Vol 21 (1-2) ◽  
pp. 137-145 ◽  
Author(s):  
William H. Harris ◽  
Arthur C. Waltman ◽  
Christos Athanasoulis ◽  
Sara Jane Wessinger ◽  
Edwin W. Salzman
Keyword(s):  
Deep Vein Thrombosis ◽  
Varicose Veins ◽  
Thromboembolic Disease ◽  
Venous Thromboembolic Disease ◽  
Vein Thrombosis ◽  
Venous Thromboembolic ◽  
Deep Vein

scholarly journals Studies on the Effects of Smoking on Vmous Thromboembolic Disease

1977 ◽  
Author(s):  
Andrew Pollock ◽  
M.J. Lewis ◽  
D.K. Mistry
Keyword(s):  
Myocardial Infarction ◽  
Deep Vein Thrombosis ◽  
Venous Thromboembolism ◽  
Significant Influence ◽  
Thromboembolic Disease ◽  
Preliminary Survey ◽  
Venous Thromboembolic Disease ◽  
Vein Thrombosis ◽  
Venous Thromboembolic ◽  
Deep Vein

It has been suggested that smoking protects against the development of deep vein thrombosis following myocardial infarction, although large studies on the effects of smoking have generally failed to show any association with venous thromboembolic disease.In a preliminary survey of patients attending an anticoagulant clinic, fewer male smokers, and more female smokers than expected, were attending after a deep vein thrombosis. Further analysis of these results, suggested that they were due, at least in part, to factors other than smoking, and a larger study was undertaken to compare the incidence of smoking in patients who had had a deep vein thrombosis, with that in the hospital outpatient population as a whole. No differences in smoking habits were found “between these groups, but small differences were observed between various groups of patients with venous thromboembolism, e.g. myocardial infarction was listed as a predisposing cause, more often than expected in male non-smokers.Thus, while smoking may effect the development of deep vein thrombosis in particular situations, e.g. after myocardial infarction, this study has failed to show any significant influence on venous thrombosis in general.

Dextran and postoperative thromboembolism

1975 ◽  
Vol 13 (11) ◽  
pp. 41-43
Keyword(s):  
Platelet Aggregation ◽  
Coagulation Factors ◽  
Venous Thromboembolic Disease ◽  
Vein Thrombosis ◽  
Dextran 70 ◽  
Lower Blood ◽  
Venous Thromboembolic ◽  
Reduce Platelet Aggregation ◽  
Increase Platelet Aggregation ◽  
Deep Vein

Two preparations of dextran have been tried for prevention of venous thromboembolic disease, dextran-40 (average m. w. 40,000) and dextran-70 (average m.w. 70,000). Dextrans reduce platelet aggregation and lower blood viscosity.1 Dextran may also reduce the peri-operative rise in the coagulation factors V and VIII.2 However, in some tests dextrans increase platelet aggregation3 and accelerate fibrin formation,4 so that only clinical trial can show whether dextran reduces the incidence of either deep-vein thrombosis or of pulmonary embolism.

High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxis

2010 ◽  
Vol 103 (01) ◽  
pp. 123-128 ◽  
Author(s):  
Jason Kerr ◽  
Lori-Ann Linkins
Keyword(s):  
Pulmonary Embolism ◽  
Knee Arthroplasty ◽  
Hip Arthroplasty ◽  
Tertiary Care ◽  
Signs And Symptoms ◽  
Joint Arthroplasty ◽  
Vein Thrombosis ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic ◽  
Deep Vein

SummaryThe in-hospital incidence of pulmonary embolism (PE) in patients undergoing elective joint arthroplasty who receive a minimum of 10 days of dalteparin prophylaxis is reported to be less than 1%. Recent clinical experience raised suspicion that the incidence of PE was significantly higher at our tertiary care institution. It was the objective of this study to determine the incidence of in-hospital PE and symptomatic deep-vein thrombosis following elective joint arthroplasty in patients who received a minimum of 10 days of dalteparin prophylaxis. Consecutive charts of patients who underwent elective joint arthroplasty at our institution between January 2008 and June 2008 were reviewed. Data on risk factors for venous thromboembolism, objectively documented venous thromboembolic events, and signs and symptoms of PE were abstracted. Patients who received concomitant warfarin in the postoperative period were excluded. The study population consisted of 437 knee arthroplasty and 246 hip arthroplasty patients. The incidence of in-hospital PE following knee arthroplasty and hip arthroplasty was 4.6% and 0.4%, respectively. One out of every 10 knee patients, and one out of every 20 hip patients underwent testing for pulmonary embolism. Pulmonary embolism was diagnosed a median of 3.5 days after knee arthroplasty. The incidence of in-hospital PE in knee arthroplasty patients who received dalteparin prophylaxis was significantly higher than expected. Potential explanations for this finding include poor efficacy of dalteparin started 12–24 hours postoperatively and/or a low threshold for ordering diagnostic imaging for PE. Studies to clarify these issues are needed.

scholarly journals Thromboembolic Disease in COVID-19

2021 ◽  
Vol 11 ◽  
pp. 16
Author(s):  
Tara Tarmey ◽  
Grace Cullen ◽  
Tanay Y. Patel ◽  
Yasmeen Kour Tandon
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Venous Thromboembolism ◽  
Clinical Manifestations ◽  
Thromboembolic Disease ◽  
Morbidity And Mortality ◽  
Respiratory Dysfunction ◽  
Vein Thrombosis ◽  
Thrombotic Complications ◽  
Deep Vein

Coronavirus disease 2019 (COVID-19) was initially recognized in late December 2019 and has quickly spread globally with over 114 million reported cases worldwide at the time of this publication. For the majority of patients infected with COVID-19, the clinical manifestations are absent or mild. In more advanced cases, severe respiratory dysfunction is the leading cause of morbidity and mortality. However, increasingly, there have been reports of increased thrombotic complications including pulmonary embolism and deep vein thrombosis seen in these patients. We present herein a series of cases of concomitant COVID-19 pneumonia and venous thromboembolism. These cases highlight the importance of clinical and radiologic vigilance to ensure this often clinically silent complication is not missed.

Contribution of a New, Rapid, Individual and Quantitative Automated D-Dimer ELISA to Exclude Pulmonary Embolism

1996 ◽  
Vol 75 (01) ◽  
pp. 011-013 ◽  
Author(s):  
Philippe de Moerloose ◽  
Sylvie Desmarais ◽  
Henri Bounameaux ◽  
Guido Reber ◽  
Arnaud Perrier ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Single Dose ◽  
Predictive Value ◽  
Quantitative Measurement ◽  
Thromboembolic Disease ◽  
Venous Thromboembolic Disease ◽  
Venous Thromboembolic ◽  
A Prospective Study ◽  
D Dimer

SummaryThe performance of a new automated ELISA for a rapid, individual and quantitative measurement of plasma D-dimer (VIDAS D-dimer) has been evaluated. First, a study of 100 patients was performed in order to choose the best couple of antibodies in comparison with an already clinically validated ELISA. Then the results were certified in a prospective study including 195 consecutive patients suspected of pulmonary embolism (PE). For a cut-off level of 500 ng/ml VIDAS D-dimer showed a sensitivity of 100% (95% confidence interval 92-100), a specificity of 37.6%, a negative predictive value of 100% (95% CI 93.3-100) and a positive predictive value of 33.1%. During a 6 months’ follow-up no patient (95% CI 0-6.4) with D-dimer <500 ng/ml presented a new suspicion of venous thromboembolic disease. These results suggest that this rapid and single-dose ELISA provides a very useful tool for the clinician to exclude on a day-to-day basis the diagnosis of PE.

scholarly journals Pulmonary Embolism- A New Challenge In Diagnosis

1970 ◽  
Vol 22 (1) ◽  
pp. 161-164
Author(s):  
Iftekhar Mahmood ◽  
MM Rahman Khan ◽  
M Khalilur Raman ◽  
ARM Saifuddin Ekram
Keyword(s):  
Risk Factors ◽  
Pulmonary Embolism ◽  
Post Partum ◽  
Diagnostic Tools ◽  
Major Surgery ◽  
X Ray ◽  
Vein Thrombosis ◽  
Limb Trauma ◽  
Deep Vein ◽  
Similar Risk

Pulmonary embolism is one of the dreadful situations demanding immediate interventions. Any delay in instituting treatment would lead to death. We have dearth of idea about the condition, many patients go undiagnosed and underevaluated. Dyspnoea, tachypnoea, hypoxemia are cardinal features of PE. Deep vein thrombosis (DVT) and PE have almost similar risk factors. Among the risk factors recent immobilization, major surgery, recent limb trauma /or surgery, pregnancy post partum etc. Important diagnostic tools like VQ scanning, assay of D-dimer could only be done only at highly specialized centers. If immediate treatment is undertaken many deaths could be averted. An X-ray chest, ECG, echocardiography could give some important diagnostic clues. DOI: 10.3329/taj.v22i1.5043 TAJ 2009; 22(1): 161-164

Sign in / Sign up

Export Citation Format

Share Document